Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor - Wikidata - awgldk - TriplyDB

Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor

Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor

http://www.wikidata.org/entity/Q27675616

about

Combotherapy and current concepts as well as future strategies for the treatment of Alzheimer's disease Computational Insights into Substrate and Site Specificities, Catalytic Mechanism, and Protonation States of the Catalytic Asp Dyad of β -Secretase Presumed LRP1-targeting transport peptide delivers β-secretase inhibitor to neurons in vitro with limited efficiency Discovery of AZD3839, a Potent and Selective BACE1 Inhibitor Clinical Candidate for the Treatment of Alzheimer Disease Discovery of an Orally Available, Brain Penetrant BACE1 Inhibitor That Affords Robust CNS Aβ Reduction Discovery, Design, and Optimization of Isoxazole Azepine BET Inhibitors InChI in the wild: an assessment of InChIKey searching in Google Identification of an Atg8-Atg3 protein-protein interaction inhibitor from the medicines for Malaria Venture Malaria Box active in blood and liver stage Plasmodium falciparum parasites Brain pyroglutamate amyloid-β is produced by cathepsin B and is reduced by the cysteine protease inhibitor E64d, representing a potential Alzheimer's disease therapeutic BACE1 inhibition induces a specific cerebrospinal fluid β-amyloid pattern that identifies drug effects in the central nervous system Tracking 20 years of compound-to-target output from literature and patents Amyloid-precursor-protein-lowering small molecules for disease modifying therapy of Alzheimer's disease A tale of two drug targets: the evolutionary history of BACE1 and BACE2 Chemoproteomic profiling reveals that cathepsin D off-target activity drives ocular toxicity of β-secretase inhibitors BACE1 across species: a comparison of the in vivo consequences of BACE1 deletion in mice and rats Preclinical trials in autosomal dominant AD: implementation of the DIAN-TU trial.Biomarkers in amyloid-β immunotherapy trials in Alzheimer's disease.Recent Progress in Alzheimer's Disease Research, Part 3: Diagnosis and Treatment.CNS amyloid-β, soluble APP-α and -β kinetics during BACE inhibition.Building a pipeline to discover and validate novel therapeutic targets and lead compounds for Alzheimer's disease.Amyloid β production is regulated by β2-adrenergic signaling-mediated post-translational modifications of the ryanodine receptor.Function, therapeutic potential and cell biology of BACE proteases: current status and future prospects.Therapeutic perspectives of drugs targeting Toll-like receptors based on immune physiopathology theory of Alzheimer's disease.Combined treatment with a BACE inhibitor and anti-Aβ antibody gantenerumab enhances amyloid reduction in APPLondon mice.BACE1 (β-secretase) inhibitors for the treatment of Alzheimer's disease Lessons from a BACE1 inhibitor trial: off-site but not off base.Targeting the β secretase BACE1 for Alzheimer's disease therapy.Modulation of amyloid precursor protein expression reduces β-amyloid deposition in a mouse model.Striking reduction of amyloid plaque burden in an Alzheimer's mouse model after chronic administration of carmustine.Development of a novel β-secretase binding assay using the AlphaScreen platform.Independent information from cerebrospinal fluid amyloid-β and florbetapir imaging in Alzheimer's disease Diurnal patterns of soluble amyloid precursor protein metabolites in the human central nervous system.Utilizing structures of CYP2D6 and BACE1 complexes to reduce risk of drug-drug interactions with a novel series of centrally efficacious BACE1 inhibitors.Alzheimer's Disease: Lessons Learned from Amyloidocentric Clinical Trials.Advances in recent patent and clinical trial drug development for Alzheimer's disease.Electroacupuncture Reduces Aβ Production and BACE1 Expression in SAMP8 Mice.An integrated multi-study analysis of intra-subject variability in cerebrospinal fluid amyloid-β concentrations collected by lumbar puncture and indwelling lumbar catheter.Near-infrared fluorescence molecular imaging of amyloid beta species and monitoring therapy in animal models of Alzheimer's disease.Future Therapeutics in Alzheimer's Disease: Development Status of BACE Inhibitors.A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-β and neuroinflammation in APP transgenic mice.

P2860

Q26829899-EBF86B14-6A50-4552-88B9-1A69845806FB Q27026144-3EAEE98A-553C-42A0-88D3-7F90685129B0 Q27341864-6B9B6739-8D72-4FC2-BA4B-ACC4F5582747 Q27674362-10F34316-DA63-4DFD-847D-0289B8639D01 Q27676383-023C051E-2ED4-419A-9456-649E78161294 Q27684210-A02E4D39-FED9-48F7-9227-1EEC0F17A3F0 Q27818912-2A9A1D41-6FF4-4EBB-8F6E-951C2EEB321F Q27861954-5EDB7C44-05C4-4527-A038-CD2DDEDDDE95 Q28235248-DE991CFC-6AC1-4982-AB33-C58E032549E1 Q28480522-A69292BB-A68E-4137-A396-1BF47B316602 Q28534695-B0A03C98-7843-4D0E-B517-2466AABA565E Q28537717-FE5F2EF9-F60B-4FF9-B82A-226976DCC061 Q28661086-5CDC2168-848B-4D93-A59B-631D5B4BD091 Q28822108-3A4E4BDD-BC14-4F7A-B714-2C9F1CC1C27F Q30361192-6416ECC9-A8D4-46FD-89DA-AB584C4B197B Q30561855-C374E9EA-306D-4F11-ACDE-3173ACBEA0CB Q30651551-6C61326F-454B-4EAA-9C0F-4BD61D6632FD Q33556068-842B6CD5-B725-4C9C-B209-AC425F13C30F Q33735544-C1EA751B-F232-49E1-8C09-11D80D46E293 Q33745617-71E4ED6B-2E34-49D0-A5EA-35651B7E7C46 Q33806103-60D623A5-0532-422D-AAA7-E87035A0ADF7 Q33862796-AB45E31B-C9CB-44A7-BC53-199EAA31F4AC Q34064026-C2946E49-A4BF-4291-B189-677D99BAD715 Q34091134-B7572FB0-3D62-47CB-A545-C6418ED88672 Q34156758-4DC9C7B8-A9F6-4E94-AB28-061E73DBD6E9 Q34381433-59EBD260-E970-4188-8867-03433FA65A2F Q34405667-2A8E825F-BE1B-4D22-9C00-6EF22210B880 Q34584517-E19253E9-DF99-4D33-B738-36D712118422 Q34636863-2486C10B-4DAC-456E-AF80-7AF0221F1BF1 Q34643036-A4A90374-1AFC-45DA-B0E3-90D99D3FFBD5 Q35119389-45EAEC05-1BF5-4DFF-B6AF-229E202FDC66 Q35124855-1B8FAC40-2386-4630-B1F9-47832FA2F853 Q35558099-FEE6131A-125D-4256-A044-EF9709FC2B58 Q35695716-CB9A663A-6CFE-4F94-8197-E5C069088184 Q35738142-52618AD6-2712-4E8F-9677-68468335A2A6 Q35898132-54D25798-DDA8-4F65-BA60-5593AFBD0C8D Q35899066-AE1F0D86-128D-4027-8FCD-AD6FAD65F1F7 Q35946092-BF6CD068-92B8-4628-A151-515369D59D1F Q35972878-C44CEBCC-164F-4A4B-9BAB-BB5CB7536145 Q36027275-023A3830-E359-454F-B532-888710D35DA3

P2860

Robust central reduction of amyloid-β in humans with an orally available, non-peptidic β-secretase inhibitor

http://www.wikidata.org/entity/Q27675616

description

2011 nî lūn-bûn

@nan

2011 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Robust central reduction of am ...... peptidic β-secretase inhibitor

@ast

Robust central reduction of am ...... peptidic β-secretase inhibitor

@en

Robust central reduction of am ...... peptidic β-secretase inhibitor

@nl

type

label

Robust central reduction of am ...... peptidic β-secretase inhibitor

@ast

Robust central reduction of am ...... peptidic β-secretase inhibitor

@en

Robust central reduction of am ...... peptidic β-secretase inhibitor

@nl

prefLabel

Robust central reduction of am ...... peptidic β-secretase inhibitor

@ast

Robust central reduction of am ...... peptidic β-secretase inhibitor

@en

Robust central reduction of am ...... peptidic β-secretase inhibitor

@nl

P1433

Q27675616-6E23722E-E1E6-4A7F-9F26-D95DCD18B735

P1476

Q27675616-88DD9810-092A-4497-BA91-3719A69F2B21

P2093

Q27675616-18063E9B-9737-456B-9358-2A1CCE12C48F

Q27675616-1AFAF1EA-E315-4307-A5E9-35A33A91CF40

Q27675616-2019C1A6-7D60-410B-BEB7-76DB8EB49DA7

Q27675616-218651E1-29E9-4314-910E-82F3CF3AC8A6

Q27675616-2632FE17-668A-42FE-97C9-91D7167D4BA6

Q27675616-2F4ADC29-7FBC-44F6-981C-EC8F9F1AFE6D

Q27675616-39F4BCBD-909B-43EA-BFB5-AD33CBE08CA7

Q27675616-5AB57CBC-38D7-4BA0-A7D5-AD3655DACE1F

Q27675616-5E29E6F4-1859-4BD1-A722-A55460B65F67

Q27675616-6A2B1BCB-F63B-4915-891D-A3E023855129

P304

Q27675616-AFCC9B5A-1B75-445C-986C-D45C7F750F67

P31

Q27675616-131F56E5-FBEC-443F-8479-9968BFBE6B19

P3181

Q27675616-F5928312-C7BD-44D0-B63D-61A47CF40DDB

P356

Q27675616-1B91458C-D9F3-4824-8F8B-D73D44A6BE89

P407

Q27675616-73BFB85E-2B59-49CB-9D5F-DE18E0F8BEEE

P433

Q27675616-A74B42EF-56BC-4B33-9C36-F779F6D6D9BC

P478

Q27675616-1DC1C4F4-7E0A-4BC2-8949-6C306237D273

P577

Q27675616-D9622C9B-1051-44EF-ABD3-5311F3C604E0

P698

Q27675616-32FBD350-5019-479D-83B3-54FE0C6AE76A

P932

Q27675616-2F8C5A26-6665-446B-8DCE-87671639FCCD

P3181

P356

JNEUROSCI.3647-11.2011

P1433

Journal of Neuroscience

P1476

Robust central reduction of am ...... peptidic β-secretase inhibitor

@en

P2093

Brian M Mathes

http://www.w3.org/2001/XMLSchema#string

Brian M Watson

http://www.w3.org/2001/XMLSchema#string

Celedon R Gonzales

http://www.w3.org/2001/XMLSchema#string

D Greg Hall

http://www.w3.org/2001/XMLSchema#string

David E Timm

http://www.w3.org/2001/XMLSchema#string

David O Calligaro

http://www.w3.org/2001/XMLSchema#string

Dustin J Mergott

http://www.w3.org/2001/XMLSchema#string

Elizabeth Smith Labell

http://www.w3.org/2001/XMLSchema#string

Ferenc Martenyi

http://www.w3.org/2001/XMLSchema#string

James E Audia

http://www.w3.org/2001/XMLSchema#string

P304

16507-16516

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2190828

http://www.w3.org/2001/XMLSchema#string

P356

10.1523/JNEUROSCI.3647-11.2011

http://www.w3.org/2001/XMLSchema#string

P407

P433

46

http://www.w3.org/2001/XMLSchema#string

P478

31

http://www.w3.org/2001/XMLSchema#string

P577

2011-11-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22090477

http://www.w3.org/2001/XMLSchema#string

P932

6633289

http://www.w3.org/2001/XMLSchema#string